Marijuana Use in Patients with Symptoms of Gastroparesis: Prevalence, Patient Characteristics, and Perceived Benefit

Background Marijuana may be used by some patients with gastroparesis (Gp) for its potential antiemetic, orexigenic, and pain-relieving effects. Aims The aim of this study was to describe the use of marijuana by patients for symptoms of Gp, assessing prevalence of use, patient characteristics, and pa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Digestive diseases and sciences 2020-08, Vol.65 (8), p.2311-2320
Hauptverfasser: Parkman, Henry P., Sharkey, Emily P., Nguyen, Linda A., Yates, Katherine P., Abell, Thomas L., Hasler, William L., Snape, William, Clarke, John, Schey, Ron, Koch, Kenneth L., Kuo, Braden, McCallum, Richard W., Sarosiek, Irene, Grover, Madhusudan, Farrugia, Gianrico, Tonascia, James, Pasricha, Pankaj J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Marijuana may be used by some patients with gastroparesis (Gp) for its potential antiemetic, orexigenic, and pain-relieving effects. Aims The aim of this study was to describe the use of marijuana by patients for symptoms of Gp, assessing prevalence of use, patient characteristics, and patients’ perceived benefit on their symptoms of Gp. Methods Patients with symptoms of Gp underwent history and physical examination, gastric emptying scintigraphy, and questionnaires assessing symptoms. Patients were asked about the current use of medications and alternative medications including marijuana. Results Fifty-nine of 506 (11.7%) patients with symptoms of Gp reported current marijuana use, being similar among patients with delayed and normal gastric emptying and similar in idiopathic and diabetic patients. Patients using marijuana were younger, more often current tobacco smokers, less likely to be a college graduate, married or have income > $50,000. Patients using marijuana had higher nausea/vomiting subscore (2.7 vs 2.1; p  = 0.002), higher upper abdominal pain subscore (3.5 vs 2.9; p  = 0.003), more likely to be using promethazine (37 vs 25%; p  = 0.05) and dronabinol (17 vs 3%; p  
ISSN:0163-2116
1573-2568
DOI:10.1007/s10620-019-05963-2